At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 748 enrolled
Drug / intervention
Mometasone Furoate Nasal Spray (MFNS) +1 moredrug
Likely dose
Mometasone Furoate Nasal Spray (MFNS) 200 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) in the Treatment of Nasal Polyps (Protocol No. P05604)
In Brief
A Phase 3 clinical trial evaluating Mometasone Furoate Nasal Spray (MFNS) and Placebo for MFNS for Nasal Polyps. Completed, enrolled 748 participants.
Detailed Summary
This study will evaluate the effectiveness and safety of MFNS in improving nasal congestion/obstruction and in reducing bilateral nasal polyps.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasal Polyps
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJun 2011
Primary CompletionFeb 2013
TodayJul 2026
First PostedJun 30, 2011
Enrollment StartJun 1, 2011
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.0 years ago
Interventions
Mometasone Furoate Nasal Spray (MFNS)drug
MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
Placebo for MFNSdrug
Two sprays in each nostril BID for up to 16 weeks